# Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

> **NCT00327678** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1080 (actual)

## Conditions studied

- Leukemia, Lymphocytic

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT00327678
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 1080 (ACTUAL)
- **Last updated:** 2016-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327678, "Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00327678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*